MET and non-small cell lung carcinoma: The co-occurrence of epidermal growth-factor receptor (EGFR) mutation and de novo or acquired MET exon 14 skipping (METex14) mutation in non-small-cell lung cancer (NSCLC) is extraordinarily rare.